Tag Archives: Portola Pharma

Portola Pharma (PTLA) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on Portola Pharma (PTLA – Research Report) today and set a price target of $42. The company’s shares opened today at $32.06. Olson noted: “PTLA reported 1Q results roughly in line with

Analysts Offer Insights on Healthcare Companies: Portola Pharma (NASDAQ: PTLA) and Rocket Pharmaceuticals Inc (NASDAQ: RCKT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Portola Pharma (PTLA – Research Report) and Rocket Pharmaceuticals Inc (RCKT – Research Report) with bullish sentiments. Portola Pharma (PTLA) Cowen &

Oppenheimer Keeps Their Buy Rating on Portola Pharma (PTLA)

Oppenheimer analyst Jay Olson maintained a Buy rating on Portola Pharma (PTLA – Research Report) today and set a price target of $42. The company’s shares opened today at $35.51. Olson said: “We examine several frequently asked questions in anticipation

Oppenheimer Keeps a Buy Rating on Portola Pharma (PTLA)

Oppenheimer analyst Jay Olson maintained a Buy rating on Portola Pharma (PTLA – Research Report) today and set a price target of $42. The company’s shares closed on Friday at $34.72. Olson wrote: “PTLA shares outperformed (+13% vs NBI +2%

Oppenheimer Remains a Buy on Portola Pharma (PTLA)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Portola Pharma (PTLA – Research Report), with a price target of $30. The company’s shares closed on Friday at $23.99. Olson observed: “We met PTLA management

A Director at Portola Pharma (NASDAQ: PTLA) is Buying Shares

Today, a Director at Portola Pharma (PTLA – Research Report), Charles Homcy, bought shares of PTLA for $234.2K. This recent transaction increases Charles Homcy’s holding in the company by 18.23% to a total of $5.77 million. Following Charles Homcy’s last